CRISPR Therapeutics

CRISPR Therapeutics

CRISPR Therapeutics

CRISPR Therapeutics is a bio-pharmaceutical company that translates CRISPR-Cas9.
Founded
2013
Raised
$158M
Follow us
Alexa global traffic share
Latest funding Show all
$56,000,000
IPO - 2016
$38,000,000
Venture capital (Series B) - 2016
New Leaf Venture Partners Franklin Templeton Investments Wellington Capital Management +1
Team Size
10+
Employees
Xconomy

CRISPR Therapeutics, Vertex Get FDA Green Light for Sickle Cell Test

MedCity News , Xconomy

CRISPR Therapeutics, ViaCyte partner on diabetes therapies

Xconomy

FDA Halts Plan for Vertex, CRISPR Therapeutics Sickle Cell Study

Health Science
Xconomy

CRISPR Therapeutics Switches CEOs As It Approaches First Clinical Study

Science Health
$56,000,000 IPO
Xconomy

CRISPR Therapeutics Raises $56M In IPO, Half Its Rivals' Haul

Science Health
$38,000,000 Venture capital (Series B)
FierceBiotech , businesswire

CRISPR Therapeutics adds $38M to Series B pot, but lags behind Parker

Funding Science Health
$64,000,000 Venture capital (Series B)
FierceBiotech

As patent battle brews, Celgene and GSK lead $64M raise for CRISPR Therapeutics

Science
Xconomy

Bayer, CRISPR Therapeutics Form $335M+ Gene Editing Venture

Health Science